Claritev Shares Recover After Comments About DOJ
By Josh Beckerman
Claritev shares recovered Monday afternoon as the company discussed its cooperation with the Justice Department.
Shares closed at $27.58 last Wednesday, posting declines of 15% and 41% for the next two trading days as Capital Forum published an article called "DOJ Launches Criminal Antitrust Probe into Claritev."
The stock was below $15 during the morning on Monday, surging after Claritev said in a securities filing that it has been cooperating fully with the DOJ. It was recently up 19% to $16.52.
Claritev, a healthcare technology, data, and insights company, said that in August 2024 it received a confidential grand jury subpoena from the DOJ's Antitrust Division in connection with an investigation regarding health insurance. At no point in the subsequent two years has the DOJ informed the company that it is the target of an investigation, Claritev said.
"We remain focused on working with clients and partners across the entire healthcare ecosystem to make healthcare more transparent, accessible, and affordable for all consumers," Claritev said.
MultiPlan changed its name to Claritev in February 2025.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 18, 2026 14:44 ET (18:44 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States